increas
scientif
knowledg
led
far
reach
advantag
humankind
like
fertil
farm
power
gener
nuclear
energi
applic
drug
aid
patient
recoveri
benefit
occasion
implic
damag
harm
advers
effect
drug
care
evalu
ratio
requir
sometim
howev
potenti
risk
difficult
estim
thu
difficult
manag
worst
result
wrong
decis
action
histor
case
swine
flu
affair
fear
swine
flu
epidem
usa
expens
nation
immun
rashli
mount
result
sever
advers
event
campaign
prematur
suspend
tragedi
nt
sign
epidem
revers
exampl
contamin
blood
product
hiv
earli
risk
aid
patient
treat
blood
product
underestim
deliber
downplay
resp
result
careless
thousand
hiv
infect
unnecessarili
occur
two
case
illustr
neither
go
way
noth
wise
today
applic
precautionari
principl
new
type
action
respons
propos
suitabl
manag
uncertain
risk
follow
develop
precautionari
principl
definit
ongo
discuss
subject
shortli
describ
exampl
demonstr
implement
environment
public
health
polici
also
medicin
focus
area
medicin
product
precautionari
measur
gain
import
regard
risk
contamin
human
product
pathogen
final
anticoagul
drug
ie
heparin
new
synthet
anticoagul
discuss
aspect
precautionari
principl
key
element
precautionari
principl
matter
activ
face
uncertainti
mean
immedi
action
must
taken
avoid
seriou
consequ
without
wait
scientif
establish
proof
danger
approach
character
slogan
like
better
safe
sorri
er
side
safeti
benefit
doubt
meanwhil
gain
intern
accept
guid
principl
environment
health
decis
make
precautionari
principl
seed
environment
sector
tabl
earli
german
vorsorgeprinzip
foresight
principl
emerg
develop
principl
german
environment
law
sinc
flourish
intern
polici
statement
agreement
initi
recogn
world
charter
natur
adopt
un
gener
assembl
subsequ
adopt
first
intern
confer
protect
north
sea
second
intern
confer
protect
north
sea
european
gener
target
ie
elimin
year
discharg
hazard
chemic
north
sea
defin
correspond
ministeri
declar
embrac
ideolog
precautionari
principl
follow
confer
integr
numer
intern
convent
agreement
rio
declar
environ
develop
order
protect
environ
precautionari
approach
shall
wide
appli
state
accord
capabl
threat
seriou
irrevers
damag
lack
full
scientif
certainti
shall
use
reason
postpon
measur
prevent
environment
degrad
year
also
offici
adopt
eu
treati
maastricht
therebi
becam
one
four
pillar
eu
environment
polici
reiter
strengthen
polit
amsterdam
treati
late
legalist
began
recommend
precautionari
approach
extend
human
health
actual
come
parti
precautionari
principl
unit
state
wingspread
confer
among
manifold
sometim
differ
definit
wingspread
statement
precautionari
principl
becom
frequent
cite
formul
tabl
activ
rais
threat
harm
environ
human
health
precautionari
measur
taken
even
caus
effect
relationship
fulli
establish
scientif
thu
explicitli
singl
function
shift
burden
proof
public
onto
propon
potenti
harm
activ
also
known
pollut
pay
principl
third
import
characterist
precautionari
approach
transpar
increas
public
particip
decis
make
consider
public
health
environ
prioriti
econom
gain
final
fourth
central
compon
explor
wide
rang
altern
possibl
harm
action
also
definit
easi
understand
differ
interpret
provok
major
critic
respons
challeng
februari
european
commiss
ec
issu
commun
precautionari
principl
clarifi
provid
guidelin
applic
accord
experiment
proceed
reason
ground
concern
ie
evid
someth
might
harm
ec
resolv
precautionari
restrict
auspic
would
proport
chosen
level
protect
nondiscriminatori
applic
consist
similar
measur
ec
also
avow
person
respons
make
decis
behalf
would
weigh
potenti
benefit
cost
build
better
understand
import
role
scienc
implement
precautionari
principl
elabor
intern
summit
scienc
precautionari
principl
held
lowel
septemb
colley
summar
explain
six
step
four
criteria
character
applic
precautionari
principl
identifi
possibl
threat
list
known
unknown
refram
situat
big
pictur
term
vigor
assess
altern
choos
cours
action
bear
burden
demonstr
risk
go
forward
owner
problem
propos
solut
honest
ethic
open
practic
precautionari
principl
includ
transpar
inform
b
inclus
stakehold
c
willing
act
face
uncertainti
account
although
precautionari
approach
go
play
increas
role
polit
decis
especi
europ
partli
prove
wise
success
principl
give
rise
major
critic
opinion
sceptic
pose
seriou
threat
sound
scienc
global
commerc
consum
choic
technolog
progress
precautionari
principl
regard
polit
idea
character
spectr
fear
emot
ignor
cloak
garb
pseudo
scienc
critic
contend
activist
ignor
complex
real
world
life
defi
year
scientif
reason
everi
choic
laden
risk
instead
object
establish
relat
manag
real
risk
precautionari
principl
lead
arbitrari
decis
base
potenti
risk
focus
nt
know
conclus
let
err
side
caution
possibl
gain
knowledg
thu
precautionari
principl
discourag
progress
eg
develop
drug
human
power
constraint
sometim
strategi
caus
even
problem
solv
exampl
european
union
moratorium
genet
manipul
gm
food
mention
discourag
small
farmer
africa
asia
use
effici
gm
agricultur
would
prevent
starv
also
could
basi
flourish
export
trade
anoth
point
critic
concern
demand
public
particip
decis
make
consid
help
progress
opinion
public
rather
base
emot
knowledg
connect
sceptic
reproach
activist
manipul
terrifi
public
hypothet
minim
risk
thu
exploit
emot
seem
howev
debat
propon
oppon
take
place
rather
theoret
level
two
extrem
ideolog
far
away
realiti
parti
partli
right
best
might
steer
middl
cours
exampl
implement
precautionari
principl
environment
polici
land
pollut
discharg
hazard
chemic
delet
biodivers
fisheri
degrad
crop
plant
eg
one
climat
chang
ozon
hole
chlorofluorocarbon
bug
new
millennium
prepar
comput
appli
numer
public
health
concern
like
potenti
toxic
chemic
eg
chlorin
water
asbesto
plastic
potenti
carcinogen
compound
persist
chemic
food
chain
eg
manmad
pesticid
antibiot
anim
food
endocrin
disrupt
compound
eg
bovin
growth
hormon
food
electr
magnet
field
bioterror
sever
acquir
respiratori
syndrom
sar
import
issu
exampl
potenti
carcinogen
compound
matter
us
nation
toxicolog
program
ntp
ntp
cooper
effort
three
feder
agenc
coordin
toxicolog
research
test
program
within
depart
health
human
servic
dhh
annual
report
carcinogen
roc
identifi
character
cancer
hazard
first
step
quantit
risk
assess
contrast
american
government
organ
european
one
wide
implement
precautionari
principl
area
food
safeti
exampl
erect
strict
rule
regard
test
commerci
food
prohibit
administr
bovin
growth
hormon
dairi
cow
wherea
us
canada
still
allow
use
latter
oppos
decis
reflect
continu
debat
chemic
scienc
societi
result
lack
knowledg
result
consider
uncertainti
reason
potenti
harm
effect
electr
magnet
field
mobil
phone
power
line
intens
controversi
discuss
exampl
action
measur
like
present
stockpil
smallpox
vaccin
obviat
bioterror
effort
fight
sever
acut
respiratori
syndrom
sar
sar
may
one
day
exampl
parti
work
success
togeth
precautionari
success
good
exampl
pure
precautionari
measur
breast
implant
longer
avail
follow
preliminari
worldwid
withdraw
manufactur
breast
implant
consist
silicon
elastom
shell
lipid
filler
base
soybean
oil
sever
year
use
altern
silicon
gel
salin
fill
breast
implant
result
concern
medic
devic
agenc
mda
safeti
data
compani
voluntarili
withdrew
product
market
march
withdraw
precautionari
measur
inform
could
gather
biolog
safeti
clinic
experi
implant
may
preliminari
data
analyt
studi
becam
avail
toxic
degrad
product
found
consid
indic
potenti
hazard
natur
filler
led
mda
hazard
notic
recommend
remov
breast
implant
compani
initi
reimburs
program
implant
replac
clinic
sampl
studi
result
expect
plan
larg
epidemiolog
studi
period
year
far
continu
research
safeti
reveal
indic
toxic
effect
implant
women
case
offici
applic
precautionari
principl
regard
adequ
damag
even
promot
research
contrast
opinion
xenotransplant
precautionari
principl
diverg
activist
xenotransplant
repres
unaccept
risk
wherea
oppon
fear
method
prevent
concern
origin
xenotransplant
ie
transplant
anim
especi
porcin
cellular
tissu
organ
graft
human
deem
promis
option
overcom
perman
shortag
donor
organ
howev
present
three
import
reason
oppos
introduct
practic
immunolog
reject
porcin
xenotranspl
physiolog
compat
thu
function
xenotranspl
human
organ
late
potenti
risk
damag
transmiss
infecti
agent
present
pig
solv
problem
reject
compat
essenti
feasibl
xenotransplant
stepwis
progress
product
new
transgen
pig
rais
hope
might
possibl
long
run
contrast
question
microbiolog
safeti
character
complet
uncertainti
risk
present
differ
virus
identifi
swine
hepat
e
viru
hendraviru
porcin
circovirus
type
ii
two
newli
identifi
herpesvirus
porcin
cytomegaloviru
particular
pig
endogen
retrovirus
perv
wherea
microorgan
may
elimin
specif
spf
anim
husbandri
breed
select
perv
repres
special
problem
perv
integr
porcin
genom
thu
transmit
recipi
relat
retroviru
known
induc
leukaemia
immun
defici
syndrom
consequ
question
aris
whether
perv
might
also
becom
pathogen
human
recent
vitro
anim
studi
suggest
spread
perv
tissu
outsid
transplant
replic
therefor
agent
could
potenti
reproduc
transplant
recipi
becom
pathogen
infecti
contact
patient
provid
sourc
potenti
epidem
date
clinic
data
indic
whether
agent
would
affect
patient
similarli
much
noth
resp
known
threat
possibl
latent
still
unknown
porcin
virus
thu
porcin
organ
may
life
save
individu
implic
virtual
unquantifi
risk
jeopard
health
wider
popul
minim
risk
framework
standard
strategi
develop
includ
guidelin
good
practic
step
xenotransplant
process
creation
coloni
spf
anim
xenotransplant
establish
enhanc
surveil
system
present
import
intensifi
research
estim
risk
instanc
pei
german
feder
agenc
sera
vaccin
recent
clone
genom
function
character
infecti
perv
develop
correspond
diagnost
test
earli
thousand
patient
receiv
blood
transfus
blood
product
like
factor
viii
factor
ix
infect
hiv
causal
agent
identifi
aid
pandem
actual
happen
miss
knowledg
uncertainti
provok
ignor
action
taught
experi
government
agenc
us
europ
cooper
industri
made
consider
effort
develop
new
regul
manufactur
control
blood
deriv
instanc
includ
care
select
examin
blood
donor
perform
hiv
hepat
b
c
viru
test
accur
document
nevertheless
iatrogen
transmiss
still
occur
betim
obviou
eg
german
stufenplanverfahren
ie
offici
regul
risk
manag
procedur
accord
german
drug
law
viru
safeti
erythrocyt
concentr
moreov
potenti
risk
may
also
aris
recent
discov
virus
like
sar
caus
coronaviru
still
unknown
virus
consequ
ongo
increas
vigil
viral
safeti
justifi
particularli
forese
futur
possibl
replac
blood
cellular
blood
product
diseas
cjd
rare
yet
rapidli
fatal
neurolog
disord
preval
one
case
per
million
peopl
per
year
besid
sporad
famili
form
iatrogen
case
transmiss
known
long
time
grow
use
therapeut
product
deriv
human
tissu
associ
rise
incid
iatrogen
cjd
case
cjd
human
growth
hormon
dura
mater
graft
corneal
transplant
stereotact
equip
also
exposur
laboratori
document
accumul
cjd
case
follow
applic
hormon
concentr
isol
hypophysi
human
cadav
distribut
immedi
discontinu
precautionari
measur
although
relationship
unknown
yet
growth
hormon
mammalian
use
treat
idiopath
infantil
urgent
need
altern
aros
problem
resolv
instant
approv
recombin
human
growth
hormon
increas
safeti
human
graft
criteria
proper
process
includ
eg
use
inactiv
method
defin
catalogu
tissu
bank
introduc
despit
small
number
known
surgic
procedur
relat
accident
inocul
patient
prion
number
guidelin
safe
work
prevent
infect
hospit
issu
supplement
train
medic
personnel
practic
univers
precaut
sinc
appear
bse
late
unit
kingdom
especi
expans
european
countri
recent
also
usa
canada
transmiss
spongiform
encephalopathi
tse
captur
increas
attent
initi
burst
bse
unit
kingdom
actual
manufactur
procedur
meat
bone
meal
mbm
chang
econom
reason
howev
expens
safeti
recogn
mbm
identifi
caus
bse
despit
first
offici
feed
ban
mbm
diseas
could
stop
sinc
risk
transmiss
unknown
consid
import
elimin
contamin
materi
food
chain
measur
like
holocaust
infect
cattl
mbm
feed
ban
certif
system
beef
current
rule
prevent
control
erad
certain
tse
defin
regul
ec
howev
appli
medicin
product
medicin
devic
cosmet
concern
medicin
product
committe
proprietari
medicin
product
cpmp
june
replac
committe
medicin
product
human
use
chmp
committe
veterinari
medicin
product
cvmp
adopt
note
guidanc
minimis
risk
transmit
anim
spongiform
encephalopathi
agent
via
human
veterinari
medicin
product
whose
second
revis
applic
juli
guidelin
concern
materi
deriv
anim
speci
human
use
product
medicin
product
set
scientif
principl
risk
minim
particular
attent
place
sourc
anim
use
manufactur
medicin
product
categor
tissu
addit
regul
design
control
manufactur
process
includ
combin
measur
give
assur
product
safeti
measur
clearli
state
precautionari
result
miss
knowledg
correspond
benefitrisk
assess
demand
regard
use
materi
deriv
anim
research
tse
promot
guidelin
perman
supplement
revis
take
account
advanc
scientif
knowledg
eg
obviou
present
elabor
third
revis
gener
requir
replac
materi
anim
speci
manufactur
biolog
pharmaceut
product
obtain
start
materi
wherev
possibl
consequ
exampl
heparin
use
europ
north
america
longer
isol
bovin
lung
porcin
intestin
mucosa
similarli
pancreat
enzym
present
exclus
obtain
swine
organ
germani
distribut
bovin
insulin
discontinu
first
vcjd
case
connect
consumpt
contamin
food
report
meanwhil
number
vcjd
case
increas
variant
form
cjd
convincingli
shown
caus
bse
pathogen
evid
influenc
perman
work
mention
note
guidanc
well
intensifi
research
tse
howev
still
high
degre
uncertainti
eg
concern
infect
variou
tissu
requir
dose
incub
time
individu
liabil
accordingli
estim
expect
incid
rang
dozen
sever
thousand
neither
suitabl
test
therapeut
measur
vaccin
obviou
vcjd
transmiss
pathogen
rumin
human
possibl
led
question
whether
may
also
transmit
human
tissu
especi
blood
blood
product
although
hitherto
indic
direct
transmiss
human
blood
blood
product
time
gain
enough
experi
short
draw
conclus
reason
precaut
tissu
distribut
assum
pathogen
prion
protein
prpsc
caus
vcjd
differ
associ
classic
cjd
occur
central
nervou
system
also
lymphat
tissu
lymph
node
tonsil
appendix
recent
publish
zanusso
et
al
prpsc
also
detect
cytoplasm
dendrit
olfactori
receptor
neuron
postmortem
specimen
olfactori
mucosa
nine
patient
sporad
cjd
moreov
accord
studi
mice
infect
show
associ
buffi
coat
also
found
plasma
infect
blood
blood
product
disprov
european
agenc
evalu
medicin
product
emea
recommend
correspond
precautionari
measur
test
individu
blood
collect
success
basic
method
rule
transmiss
pathogen
blood
develop
detect
techniqu
vcjd
pathogen
intensifi
long
suitabl
screen
test
avail
first
import
prevent
strategi
exclus
blood
donor
expos
possibl
risk
infect
thu
blood
plasma
uk
must
use
manufactur
blood
deriv
longer
furthermor
person
exclud
potenti
blood
donor
spent
total
one
year
uk
northern
ireland
expand
exclus
individu
receiv
blood
transfus
opin
accept
view
prevail
blood
shortag
second
measur
blood
cellular
blood
compon
deplet
buffi
coat
leucoreduct
remov
potenti
present
vcjd
pathogen
although
real
effect
leucoreduct
tse
infect
still
proven
remov
leukocyt
anyway
advantag
advers
effect
caus
leucocyt
concern
medicin
product
manufactur
process
optim
effect
infect
plasma
reduc
alreadi
indic
avail
data
suggest
recal
batch
medicin
product
donor
plasma
pool
subsequ
develop
vcjd
regard
measur
consid
thinkabl
risk
vcjd
transmiss
exchang
real
risk
caus
shortag
blood
blood
product
guarante
stabil
blood
suppli
suitabl
promot
motiv
campaign
recruit
blood
donor
carri
addit
germani
start
initi
optimum
use
blood
product
gener
recommend
mean
avoid
use
blood
blood
product
wherev
possibl
repres
best
way
reduc
potenti
risk
transmiss
final
substitut
medicin
product
altern
product
recombin
protein
well
develop
substitut
albumin
encourag
impact
precautionari
measur
practic
becom
obviou
withdraw
metrodin
hp
high
puriti
uk
februari
metrodin
hp
hormon
predominantli
use
strong
stimul
ovari
women
undergo
vitro
fertilis
ivf
prepar
urin
collect
itali
one
case
vcjd
recent
confirm
although
indic
transmiss
vcjd
via
urin
product
deriv
urin
committe
safeti
medicin
csm
advis
metrodin
hp
longer
use
precaut
remot
possibl
might
infect
vcjd
pathogen
recommend
substitut
avail
adequ
altern
product
recombin
protein
wait
whether
possibl
origin
preced
withdraw
medicin
product
human
anim
origin
altern
avail
besid
gonadotrophin
candid
instanc
insulin
blood
coagul
factor
fviii
fix
urokinas
discontinu
product
would
drastic
chang
medic
practic
use
recombin
analogu
anyway
expand
trend
substitut
anim
protein
use
medicin
recombin
altern
result
reduc
contamin
risk
pivot
advantag
product
independ
limit
dispos
natur
raw
materi
even
becom
avail
recombin
technolog
tabl
higher
degre
puriti
reduc
risk
advers
drug
reaction
adr
caus
concomit
protein
substanc
better
standard
natur
concentr
eg
gonadotrophin
known
insulin
protein
better
toler
induc
less
immunolog
reaction
addit
recombin
technolog
enabl
specif
modif
result
improv
pharmacolog
profil
tabl
nevertheless
recombin
protein
also
matter
precautionari
approach
accordingli
approv
recombin
protein
special
requir
qualiti
safeti
met
extrem
costli
consequ
may
even
constrain
medicin
progress
exampl
although
effici
express
system
mostli
use
baculoviru
express
system
sf
insect
cell
could
prevail
yet
requir
expens
safeti
studi
even
recombin
protein
gener
free
risk
viral
contamin
manifold
potenti
sourc
contamin
rang
virus
endogen
present
product
cell
line
eg
parvoviru
hantaviru
cho
cell
virus
use
induc
gene
express
reagent
addit
appli
product
purif
cultur
media
trypsin
growth
factor
monoclon
antibodi
drug
formul
excipi
like
serum
albumin
instanc
initi
optim
escap
risk
viru
hbv
hcv
hiv
infect
factor
viii
recombin
analogu
dampen
observ
seroconvers
parvoviru
applic
recombin
factor
viii
result
parvoviru
albumin
use
excipi
albumin
use
excipi
also
consid
potenti
risk
factor
vcjd
transmiss
prevent
measur
develop
substitut
albumin
recommend
accord
stabil
human
serum
albumin
contain
epoetin
alfa
formul
replac
polysorb
glycin
time
increas
incid
pure
red
cell
aplasia
prca
patient
chronic
renal
failur
subcutan
administr
epoetin
alfa
observ
sever
advers
event
caus
neutral
antierythropoietin
antibodi
suggest
result
chang
formul
protein
adequ
stabil
result
format
immunogen
aggreg
consequ
applic
precautionari
measur
recombin
protein
benefit
lead
real
threat
patient
regard
also
case
like
recent
report
anaphylact
reaction
caus
thrombin
inhibitor
lepirudin
recombin
hirudin
question
aris
whether
recent
euphoria
recombin
protein
drug
futur
realli
justifi
fact
pharmaceut
research
conform
principl
small
beauti
focus
identif
target
ration
design
specif
act
drug
like
small
synthet
thrombin
inhibitor
melagatran
safeti
anoth
porcin
medicin
product
consider
name
pancreat
enzym
prepar
indic
pancreat
enzym
insuffici
cystic
fibrosi
reason
potenti
contamin
porcin
parvoviru
ppp
parvovirus
small
envelopeless
lead
either
specif
diseas
complex
syndrom
suscept
host
despit
high
normal
condit
parvovirus
consid
abl
cross
speci
barrier
outstand
physicochem
resist
widespread
contamin
biolog
pharmaceut
product
difficult
remov
inactiv
practic
relev
becom
obviou
mention
parvoviru
human
serum
albumin
factor
viii
prepar
correspond
seroconvers
patient
howev
neither
probabl
transmiss
ppp
human
pathogen
known
although
porcin
pancreat
enzym
use
mani
year
clinic
case
ppp
infect
known
therefor
result
miss
altern
pancreat
enzym
distribut
final
allow
continu
thu
case
exemplarili
demonstr
consider
precautionari
principl
also
implic
accur
benefitrisk
analysi
present
wide
use
medicin
product
isol
porcin
materi
heparin
refer
unfraction
heparin
ufh
variou
low
molecular
weight
heparin
lmwh
still
appli
drug
prophylaxi
therapi
thromboembol
diseas
clinic
case
viral
contamin
would
make
question
viral
safeti
porcin
heparin
regardless
recent
offici
decis
concern
drug
reason
make
altern
heparin
desir
discontinu
bovin
heparin
result
bse
problem
heparin
use
europ
north
america
isol
porcin
intestin
mucosa
sizeabl
shortag
raw
materi
present
mucosa
million
pig
need
yearli
product
heparin
treat
million
peopl
worldwid
us
germani
franc
million
heparin
dose
appli
wherebi
percentag
lmwh
amount
respect
data
imsmida
need
still
increas
heparin
use
countri
grow
number
indic
increasingli
longer
period
exampl
sale
volum
heparin
germani
increas
million
million
correspond
million
standard
dose
sale
heparin
dose
us
increas
million
million
dose
data
imsmida
furthermor
product
prevail
lmwh
even
raw
heparin
requir
accord
busi
report
pharmaceut
industri
last
year
sale
volum
lmwh
increas
per
year
anoth
point
natur
product
heparin
polydispers
mixtur
molecul
show
wide
variat
composit
prepar
gener
contain
dermatan
heparin
sulfat
vari
extent
respect
composit
heparin
prepar
depend
individu
manufactur
process
manifold
paramet
rang
use
pig
subspeci
condit
anim
husbandri
process
mucosa
extract
raw
heparin
final
purif
influenc
final
heparin
constitut
result
larg
differ
variou
heparin
prepar
well
consider
variat
ultim
becom
manifest
differ
biolog
activ
biolog
activ
compris
acceler
inhibit
thrombin
factor
xa
thought
mainli
respons
antithrombot
activ
heparin
exhibit
wide
rang
biolog
effect
thu
specif
act
drug
rather
multival
biomodul
develop
lmwh
drawback
ufh
like
unfavour
pharmacokinet
profil
could
improv
howev
regard
efficaci
safeti
none
heparin
consid
optim
despit
limit
heparin
use
miss
suitabl
altern
antithrombot
drug
approv
fondaparinux
fig
situat
chang
fondaparinux
first
one
new
class
antithrombot
agent
ie
select
inhibitor
factor
xa
fulli
synthet
produc
chemic
defin
pentasaccharid
specif
bind
antithrombin
high
affin
way
select
inhibit
fxa
efficaci
safeti
fondaparinux
examin
sever
phase
ii
iii
clinic
trial
four
phase
iii
studi
prophylaxi
surgeri
involv
patient
undergo
major
orthopaed
surgeri
lower
limb
fondaparinux
reduc
risk
venou
thromboembol
vte
proxim
deep
vein
thrombosi
compar
common
lmwh
enoxaparin
base
phlebograph
detect
thrombosi
intern
accept
efficaci
endpoint
benefit
extend
thromboprophylaxi
fondaparinux
hip
fractur
surgeri
patient
also
demonstr
reduct
symtpomat
vte
fondaparinux
also
show
benefit
prevent
vvte
surgic
medic
set
treatment
patient
vte
accord
clinic
studi
fondaparinux
therapi
current
avail
treatment
treatment
patient
fondaparinux
case
thrombocytopenia
hit
type
ii
far
report
plasma
contain
antibodi
found
consequ
fondaparinux
use
accord
approv
regimen
provid
effect
safe
postop
regimen
orthopaed
surgeri
patient
addit
simpl
easi
use
independ
clinic
profil
characterist
fondaparinux
concern
pharmaceut
qualiti
advantag
compar
heparin
addit
fondaparinux
line
current
effort
health
polici
implement
precautionari
principl
gener
total
chemic
synthesi
potenti
risk
contamin
variabl
exclud
furthermor
synthet
antithrombot
develop
synthet
thrombin
inhibitor
melagatran
oral
avail
prodrug
ximelagatran
complet
mutual
recognit
procedur
europ
may
introduc
germani
june
year
although
intens
research
new
antithrombot
drug
last
decad
certainli
driven
mainli
clinic
need
effect
safer
drug
current
trend
drug
develop
also
consid
suggest
health
author
replac
product
health
care
system
will
pay
cost
combin
innov
therapi
could
becom
independ
use
anim
product
antithrombot
therapi
last
decad
precautionari
principl
gain
import
approach
manag
uncertain
risk
prevent
damag
environ
human
health
key
element
take
action
even
caus
effect
relationship
fulli
establish
scientif
meantim
increasingli
implement
medicin
import
subject
potenti
threat
medicin
product
human
anim
origin
manifold
offici
regul
state
improv
safeti
particularli
avoid
infect
virus
tse
pathogen
anim
medicin
product
best
prevent
measur
substitut
altern
product
whenev
possibl
contrast
opinion
sceptic
promot
research
scienc
new
antithrombot
drug
fondaparinux
exemplari
demonstr
princip
possibl
becom
independ
product
futur
consid
ultim
offici
requir
met
healthcar
system
public
will
pay
cost
correspond
innov
medicin
product
